scorecardresearch
Friday, August 29, 2025
TopicCovaxin

Topic: Covaxin

For Covaxin to get emergency use approval, WHO needs ‘more information’ from Bharat Biotech

Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency.

Bharat Biotech submits 90% documents to WHO to obtain emergency use listing for Covaxin

The Hyderabad-based Bharat Biotech Ltd is expected to submit the remaining documents by June and is confident about obtaining WHO's authorisation for EUL, sources said.

Paediatric clinical trials of Covaxin might begin in June, says Bharat Biotech official

The trials would be on children aged 2-18 years for which Bharat Biotech may get the licence in the third quarter of this year, a FICCI Ladies Organisation press release Sunday said.

Delhi HC seeks Centre’s stand on PIL against Covaxin trial on 2-18 age group

HC bench issues notice to Centre and Bharat Biotech seeking their stand by 15 July on the petition.

Covaxin works against Indian-origin variant, finds ICMR-Bharat Biotech in lab tests

Team collected blood samples of patients who had recovered from Covid along with those who had been vaccinated with Covaxin. But experts say lab tests aren’t enough.

Covaxin stock for those aged above 45 to last only one day, says Delhi AAP MLA Atishi

According to the Aam Aadmi Party legislator, 1.18 lakh people in Delhi were vaccinated on 15 May and around 10.5 lakh people have taken both vaccine doses so far.

Maharashtra suspends vaccination drive for 18-45 age group, Delhi runs out of Covaxin

While the vaccination drive appeared to be faltering in several states, Union Health Minister Harsh Vardhan urged the state govts to first focus more on second dose vaccinations.

Disheartening to see some states complaining about Covaxin supply intentions — Bharat Biotech

In a tweet Wednesday, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on 10 May.

Modi govt expert panel recommends Covaxin for phase 2/3 clinical trials on 2-18-yr-olds

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, is being used on adults in India's ongoing Covid vaccination drive.

Delhi’s Covaxin stock for 18-44 age group over, will be forced to shut 125 centres: AAP

Flagging shortage of Covid vaccine in the national capital, AAP leader Atishi informed that 2,67,690 doses of Covishield will be supplied by the Centre to Delhi by Tuesday evening.

On Camera

Mohan Bhagwat’s U-turn on ‘retire at 75’ is a Hindu succession problem

RSS chief Mohan Bhagwat has backtracked on his retirement rules. The ‘75-year rule’ was applied selectively to sideline some leaders, but it doesn’t apply to the top brass.

Easy loans, uneasy ‘debt traps’. Women harassed by private lenders ask ‘who will restore lost dignity?’

A public meeting, where the women voiced their protest, took place this month in Delhi, grounded on the findings of an AIDWA survey, covering 9,000 women borrowers.

Post-Sindoor, joint doctrine tasks Special Forces with fighting info warfare & countering propaganda

Joint Doctrine for Special Forces Operations, released Wednesday, also outlines plans for the future expansion of AFSOD and the creation of Joint Service Training Institutes.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.